Embryonic muscle-type nicotinic acetylcholine receptor (Embryonic nAChR)

The embryonic muscle-type nicotinic acetylcholine receptor (nAChR) is a pentameric ligand-gated ion channel essential for signaling at the neuromuscular junction during fetal development. It is structurally characterized by the subunit composition (alpha1)2-beta1-gamma-delta, which distinguishes it from the adult isoform where the gamma subunit is replaced by an epsilon subunit (UniProt: P07510). This receptor mediates the influx of cations, primarily sodium and calcium, upon binding of the neurotransmitter acetylcholine, leading to muscle membrane depolarization and subsequent contraction (StatPearls: Physiology, Neuromuscular Junction). While typically downregulated and replaced by the adult form after birth, the embryonic nAChR can be re-expressed across the entire muscle membrane following denervation, immobilization, or severe thermal injury (PubMed: 15505151). This re-expression is clinically significant as the embryonic form is hypersensitive to depolarizing relaxants like succinylcholine, which can trigger massive potassium release and cardiac arrest. It also serves as a primary target for autoantibodies in Myasthenia gravis and is implicated in the pathogenesis of Escobar syndrome (NCBI Gene: 1146). Pharmacologically, it is a critical target for neuromuscular blocking agents used to achieve muscle relaxation during surgical anesthesia.

Other names

Fetal muscle-type nicotinic acetylcholine receptorAlpha2-beta-gamma-delta nicotinic acetylcholine receptorGamma-containing muscle nicotinic acetylcholine receptorAChR-gamma

Drugs targeting this receptor function as either depolarizing agonists that cause persistent activation and subsequent desensitization of the muscle membrane, or as non-depolarizing competitive antagonists that bind to the alpha subunits to prevent acetylcholine from initiating an action potential, thereby inducing muscle paralysis.